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A major function of a subfamily of NLR (nucleotide-binding domain, leucine-rich repeat containing, or NOD-
like receptor) proteins is in inflammasome activation, which has been implicated in a multitude of disease
models and human diseases. This work will highlight key progress in understanding the mechanisms that
activate the best-studied NLRs (NLRP3, NLRC4, NAIP, and NLRP1) and in uncovering inflammasome NLRs.Introduction
The inflammasome that leads to caspase-1 protease activation
has broad biologic and clinical impact. This review will focus
on recent discoveries made in the last two to three years
that have uncovered signaling pathways that lead to NLR
(nucleotide-binding domain, leucine-rich repeat containing, or
NOD-like receptor) inflammasome activation, roles of NLRs in
canonical and noncanonical inflammasome activation, and
several other inflammasome-forming NLRs besides NLRP3.
The pathological effects of inflammasome activation in diseases
have been reviewed extensively and will not be discussed here
(Lamkanfi and Dixit, 2012; Strowig et al., 2012).
Mechanisms of NLRP3 Inflammasome Activation
Despite of the rapid discovery of activating agents of the NLRP3
inflammasome, uncovering the precise molecular mechanisms
for NLRP3 inflammasome activation remains challenging. How-
ever, recent studies have identified both mechanisms and mole-
cules that are involved in NLRP3 inflammasome activation in
response to various stimuli.
Numerous recent studies have evoked an essential role of
mitochondria in NLRP3 inflammasome activation by mecha-
nisms that could be generalized into two categories. First, the
mitochondria provide an ideal platform for assembly of the
NLRP3 inflammasome complex. Second, NLRP3 may be acti-
vated directly by mitochondria-derived effector molecules such
as mitochondrial reactive oxygen species (mROS), mitochon-
drial DNA (mtDNA), and phospholipid cardiolipin (Figure 1).
Previous studies suggest that NLRP3 inflammasome activa-
tion induces the relocalization of NLRP3 from a cytosolic
compartment to the mitochondria, based on both biochemical
and imaging assays (Subramanian et al., 2013; Zhou et al.,
2011). This process requires the first six amino acids at the N ter-
minus of the PYRIN domain of NLRP3, which are also essential
for optimal NLRP3 inflammasome activation. The mitochondrial
antiviral signaling (MAVS) adaptor protein is shown to mediate
this process by associating with NLRP3 (Subramanian et al.,
2013). Of note, macrophages from MAVS-deficient (Mavs/)
mice show a defective NLRP3 inflammasome activation in
response to ATP and nigericin (a microbial toxin that acts as
potassium ionophore and activates the NLRP3 inflammasome)432 Immunity 39, September 19, 2013 ª2013 Elsevier Inc.selectively, but not to crystalline reagents such as alum and
silica, suggesting that MAVS is not absolutely required for
NLRP3 activation (Subramanian et al., 2013). The mitochondrial
recruitment of NLRP3 and optimal NLRP3 inflammasome activa-
tion also requires the functional microtubule system and signals
through a metabolic signaling axis including NAD+-sirtuin
2-tubulin-dynein (Misawa et al., 2013).
There has been a long-standing debate about the role of
mROS in NLRP3 activation. Many studies have shown that
increased mROS activates the NLRP3 inflammasome (Zhou
et al., 2010, 2011), but at least one study argues that instead of
activating NLRP3, increased ROS promotes NLRP3 expression
at the transcriptional level (Bauernfeind et al., 2011). These
discordant conclusions may be due to a wide usage of pharma-
cological activators or inhibitors of ROS and mitochondrial func-
tions, which cause various outcomes depending on the dosage,
duration, and cell types. Notably, another study argues that a
drop in cytosolic K+, but not mitochondrial perturbation, causes
NLRP3 activation (Mun˜oz-Planillo et al., 2013). Whether this
study has truly defined the convergent point between all
NLRP3 agonists needs additional investigation. Mitochondria
may also contribute to NLRP3 activation by releasing mtDNA
(Nakahira et al., 2011; Shimada et al., 2012) or phospholipid car-
diolipin (Iyer et al., 2013).
Because of the variety of molecular structures such as pattern-
associated molecular pattern (PAMP)- and damage-associated
molecular pattern (DAMP)-containing molecules that can
activate the NLRP3 inflammasome, it is generally accepted
that NLRP3 is not likely to recognize these motifs, but rather
senses the disturbance of cellular homeostasis, i.e., cell stress,
such as the changes in redox status or cellular ion concentra-
tion. One of these typical cell stresses originates from the
loss of endoplasmic reticulum (ER) homeostasis, namely ER
stress. ER stress is induced by the accumulation of unfolded
protein in the ER or the disruption of ER Ca2+ and activates the
downstream unfolded protein response (UPR) (Cox et al.,
1997). The role of ER stress has been implicated in a multitude
of human diseases (Hotamisligil, 2010; Ozcan and Tabas,
2012; Ron and Walter, 2007; Todd et al., 2008; Zhang and Kauf-
man, 2008). Recent studies suggest that ER stress can activate
NLRP3 (Figure 1). Multiple ER stressors induce NLRP3- and ASC
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Figure 1. Schematic of the NLRP3
Inflammasome Activation in Response to
Mitochondria, ER, and Ca2+ Signals
The activation of the NLRP3 inflammasome by its
typical stimuli such as ATP, toxin, and crystalline
reagents involve mitochondria-derived signals
such as mROS, mtDNA, and cadiolipin. The re-
localization of NLRP3 from the cytosol to mito-
chondria is MAVS dependent and is pivotal for
optimal inflammasome activation. GBP5 pro-
motes NLRP3 signaling to ASC. ER stress has
been reported to activate the NLRP3 in-
flammasome through a mechanism that seems
not to require the typical unfolded protein
response pathway. Elevated intracellular Ca2+
and/or decreased intracellular K+ are required for
NLRP3 inflammasome activation. Either LPS or
TNF will prime NLRP3 into a ready state. When
these agonists synergize with IFN-b or IFN-g,
iNOS is hyperinduced, resulting in inhibition of
NLRP3 by nitrosylation.
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dependent caspase-1 cleavage followed by IL-1b maturation
(Menu et al., 2012). Interestingly, none of three known UPR initi-
ators (PERK, IRE1a, and ATF6) seems to be required for ER
stress-induced NLRP3 activation. Two recent studies have
confirmed ER stress-activated NLRP3 and further indicated
thioredoxin-interacting protein (TXNIP) as a key mediator (Lerner
et al., 2012; Oslowski et al., 2012). Because TXNIP expression is
increased only by ER stressors and not by ATP, onemay hypoth-
esize that TXNIP is required for NLRP3 activation only by ER
stress, not by other stimuli. These studies may reconcile the
long-term debate about whether TXNIP plays a role in NLRP3
activation (Masters et al., 2010; Zhou et al., 2010). However, sig-
nificant questions remain to be answered. For example, is
TXNIP-mediated NLRP3 activation cell type specific, such as
in pancreatic b cells but not in myeloid cells? Is TXNIP involved
in NF-kB-dependent signal-1 (pro-IL-1b generation and NLRP3
upregulation), or signal-2 (inflammasome activation), or both,
since ER stress can clearly enhance both signals? Further inves-
tigation of the mechanisms of ER stress-induced NLRP3 inflam-
masome activation is warranted.
The importance of intracellular Ca2+ ([Ca2+]i) in IL-1b process-
ing (a downstream event after NLRP3 activation) was initially
based on the observation that pretreatment of cells with Ca2+
chelator BAPTA-AM abolished ATP- and nigericin-induced
IL-1bmaturation (Brough et al., 2003). Although ATP or nigericinImmunity 39, Secauses rapid Ca2+ influx and a sharp in-
crease in [Ca2+]i, extracellular Ca
2+ influx
is not absolutely required for the cleavage
of caspase-1 and IL-1b. This is due to
Ca2+ release from ER, the major intracel-
lular Ca2+ store. ATP stimulation leads to
the translocation and activation of phos-
pholipase C (PLC), which catalyzes
inositol triphosphate (IP3) production.
IP3 causes rapid Ca
2+ release from ER
by activating an IP3 receptor on ERmem-
branes, and increased [Ca2+]i subse-
quently triggers extracellular Ca2+ influx
through store-operated Ca2+ entry(SOCE) (Feske et al., 2012). Treatment of cells with pharmaco-
logical inhibitors of PLC, IP3 receptor (IP3R), or SOCE signifi-
cantly decreases NLRP3 inflammasome activation (Figure 1;
Murakami et al., 2012).
How does elevated intracellular Ca2+ promote NLRP3 inflam-
masome activation? One study suggests that mitochondrial
damage induced by Ca2+ causes NLRP3 inflammasome activa-
tion through mROS and mtDNA release (Murakami et al., 2012).
This is consistent with the concept that Ca2+ mobilization from
the ER to the mitochondria occurs rapidly and mitochondrial
Ca2+ overload causes mitochondrial damage (Rizzuto et al.,
1998, 2012). Therefore, inhibition of mitochondrial Ca2+ uptake
by silencing mitochondrial Ca2+ uniporter (MCU) abolishes
NLRP3-dependent IL-1b release (Triantafilou et al., 2013a).
Two other studies have reported the effect of G protein-coupled
Ca2+-sensing receptors, CASR and GPRC6A, in NLRP3 activa-
tion (Lee et al., 2012; Rossol et al., 2012). CASR activation by
extracellular Ca2+ triggers positive feedback signaling cascade
involving PLC-IP3-IP3R, which leads to increased [Ca
2+]i and
NLRP3 activation. Increased [Ca2+]i is also required for NLRP3
activation by encephalomyocarditis virus (Ito et al., 2012).
CASR stimulation reduces intracellular cyclic AMP (cAMP),
which has been suggested to be an inhibitor of NLRP3 (Lee
et al., 2012). Other studies have reported that Ca2+-permeable
channels, transient potential melastatin-like 2 (TRPM2) (Zhong
et al., 2013), TRPV2, and TRPM7 (Compan et al., 2012), areptember 19, 2013 ª2013 Elsevier Inc. 433
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reagents, liposome, and extracellular hypo-osmolarity, respec-
tively. Therefore, NLRP3 activation requires increased [Ca2+]i
and Ca2+-dependent signaling.
The conceptual similarity between the inflammasome (NLR or
a non-NLR sensor, ASC, and caspase-1) and the apoptosome
(Apaf-1, cytochrome c, and caspase-9) has been increasingly
appreciated: they both formmultiprotein complexes in response
to specific activating signals and they both control inflammation
and cell death. Recent studies reveal that the inhibitors of
apoptosis protein (IAPs), which are critical inhibitors of apoptotic
signaling, mediate inflammasome activation in both positive and
negative manner. The cIAPs (cIAP1 and cIAP2) associate with
caspase-1 and promote its K63-linked polyubiquitination, which
is essential for NLRP3 activation. The deletion of the gene en-
coding cIAP2 (Birc3/) results in impaired NLRP3 activation
(Labbe´ et al., 2011). In contrast, the deletion of all three IAPs
(XIAP, cIAP1, and cIAP2) leads to NLRP3-caspase-1-dependent
and caspase-8-dependent IL-1b activation, which is mediated
by RIP3 (receptor-interacting protein 3)-dependent ROS gener-
ation (Vince et al., 2012). The cause of conflicting data from the
above two studies is not clear, although it may be due to usage
of different gene-deletion mice strains. Therefore, targeting IAPs
by Smac (second mitochondria-derived activator of caspase)
mimetics could be a therapeutic regimen for IL-1b-mediated in-
flammatory diseases.
Caspase-8, an important effector apoptosis caspase, can
trigger IL-1b and IL-18 cleavage by the engagement of cell
surface receptors including the death-inducing receptor FAS
(CD95) (Bossaller et al., 2012; Miwa et al., 1998), Toll-like recep-
tors (Maelfait et al., 2008), and the C-type lectin receptor
dectin-1 (Gringhuis et al., 2012). Caspase-8-mediated IL-1b
activation does not require any known inflammasome-forming
NLR molecules, although ASC is required. Paradoxically,
Casp8 deletion results in a spontaneous NLRP3 inflammasome
activation that is dependent on RIP3-MLKL (mixed lineage
kinase domain-like protein)-mitochondrial protein phosphatase
PGAM5 signaling (Kang et al., 2013). These observations indi-
cate that caspase-8 regulates IL-1b activation by two distinct
mechanisms. Active caspase-8 can directly process IL-1b in
response to specific extracellular signals, whereas loss of
caspase-8 causes the disruption of cell homeostasis and leads
to NLRP3 activation through RIP3 signaling. Importantly, these
studies are consistent with amechanismwhereby RIP3 signaling
functions downstream of caspase-8 and leads to necrosis and
animal lethality in the absence of caspase-8 (Kaiser et al.,
2011; Oberst et al., 2011) and highlight a complex role of
caspase-8-RIP3 signaling in cell death and inflammation.
Recent studies have also focused on the role of posttransla-
tional modification in inflammasome activity. Mishra et al.
(2013) has reported a regulatory mechanism limiting the activa-
tion of NLRP3, but not AIM2, inflammasome rendered by the
interferon-g-nitric oxide synthase-2 nitric oxide (IFN-g-NOS2-
NO) pathway (Mishra et al., 2013). This inhibitory effect is
due to NO-mediated S-nitrosylation of NLRP3, which leads to
impaired assembly of NLRP3 inflammasome. This negative
regulation may be essential to dampen NLRP3 signaling and is
suggested to be a protective mechanism during endotoxin chal-
lenge (Mao et al., 2013). Furthermore, ATP-induced NLRP3 in-434 Immunity 39, September 19, 2013 ª2013 Elsevier Inc.flammasome activation is strongly inhibited when NLRP3 is
ubiquitinated or NLRP3 deubiquitination is blocked, which indi-
cates that NLRP3 deubiquitination is an essential posttransla-
tional protein modification for NLRP3 activation (Juliana et al.,
2012; Lopez-Castejon et al., 2013; Py et al., 2013). NLRP3
deubiquitination is mediated by BRCC3, a member of JAMM
domain-containing Zn2+ metalloprotease deubiquitinating en-
zyme family, therefore providing a therapeutic target for IL-
1b-associated inflammatory diseases.
Players in NLRP3 Inflammasome Activation
Recent studies have reported two inflammasome regulators:
guanylate-binding protein 5 (GBP5) (Shenoy et al., 2012) and
double-stranded RNA-dependent protein kinase (PKR) (Lu
et al., 2012). GBP5 belongs to the 65 kD GBP gene family and
promotes NLRP3 inflammasome activation by ATP, nigericin,
and bacteria, but not crystalline agents. GBP5 directly binds to
the PYRIN domain of NLRP3 via its GTPase domain. GBP5 forms
a tetrameric structure and stimulates NLRP3-ASC oligomeriza-
tion. In contrast to the selective effect of GBP5 on NLRP3, PKR
has recently been shown to contribute to the activation of all
known inflammasomes, including NLRP1, NLRP3, NLRP4, and
AIM2 inflammasomes. Loss of PKR results in attenuated IL-1b
and IL-18 cleavage in response to a broad array of stimuli. Inter-
estingly, GBP5 and PKR have been indicated in host defense
against bacterial and viral infection, respectively, thereby high-
lighting complex cross-regulation among multiple inflammatory
signaling pathways. However, the effect of PKR on NLRP3 in-
flammasome has been recently disputed in one report. With cells
from two independent Pkr-deletion mouse strains, PKR does not
show any effect in NLRP3 activation, although it does affect LPS-
induced NOS2 upregulation (He et al., 2013). The same gene
mutant mouse stains were employed in these studies, so the
reason for the different conclusions remains unclear.
Other NLR Inflammasomes
Seminal findings regarding NLRC4, NLRP1 inflammasome, and
other inflammasome NLRs have been reported. These findings
are summarized below.
The NLRC4 inflammasome detects bacterial proteins in the
cytosolic compartment as markers for the activity of bacterial
type III (T3SS) and IV (T4SS) secretion systems or cytosolic inva-
sion by flagellated bacteria. T3SS and T4SS are virulence factors
that act asmolecular syringes, transferring bacterial effector pro-
teins through a hollow needle-like structure into host cell cytosol.
The effector proteins reprogram host cell physiology to the
benefit of the bacterial pathogen. The effector proteins are vari-
able between bacteria and evolve quickly and are thus poor tar-
gets for innate immune detection. Instead, NLRC4 responds to
accidental injection of three conserved proteins: flagellin, rod,
and needle (Kofoed and Vance, 2011; Miao et al., 2010; Zhao
et al., 2011). The reason why these proteins are accidentally
injected is more thoroughly discussed elsewhere (Miao and
Warren, 2010).
NLRC4 is unique among inflammasomes in that it is a down-
stream adaptor protein from the upstream receptor NLRs in
the NAIP family (Figure 2). NAIPs appear to directly bind to one
of the three agonists: flagellin, T3SS rod, or T3SS needle. For
example, in C57BL/6 mice there are four NAIPs: NAIP1 detects
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Figure 2. Canonical and Noncanonical
Inflammasome Activation Pathways
Canonical inflammasomes including NLRP3,
AIM2, and NLRC4 activate caspase-1. NLRP3 or
AIM2 recruits caspase-1 through the adaptor
protein ASC via Pyrin-Pyrin homotypic in-
teractions. The activated caspase-1 results in its
proteolytic maturation to the p10 and p20 frag-
ments and subsequent IL-1b and IL-18 cleavage
and secretion. NLRC4 contains a CARD domain
and directly binds to the CARD of caspase-1
through homotypic interaction, triggering cytokine
(IL-1b and IL-18) maturation and pyroptosis.
Noncanonical inflammasome activation leads to
caspase-11-dependent pyroptosis. Caspase-11
activation also triggers NLRP3 activation via an
unknown mechanism (not shown).
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Smith, R.E. Vance, and E.A.M., unpublished data), NAIP2 detect
rod, and NAIP5 and NAIP6 detect flagellins (Kofoed and Vance,
2011; Zhao et al., 2011). Interestingly, in humans there appears
to be only one NAIP that responds to the needle protein (Zhao
et al., 2011). How NAIPs and NLRC4 interact with each other re-
mains unknown. They may form mixed inflammasome hubs, or
NAIP may signal to activate NLRC4 (Halff et al., 2012).
The latter hypothesis could explain the recent finding that
NLRC4 phosphorylation is critical for its activity. Protein kinase
C delta (PKCd) was found to be the kinase responsible for this
modification, and Prkcd/ macrophages were mostly, but not
completely, recalcitrant to NLRC4 activation (Qu et al., 2012). It
is tempting to speculate that the NAIP inflammasome oligomer-
ization somehow directs PKCd to phosphorylate NLRC4. The
NLRC4 structure was recently solved, and surprisingly appar-
ently inactive NLRC4 is phosphorylated (Hu et al., 2013). How-
ever, the purified protein was generated in insect cells, and a
construct lacking the CARD domain as well as 22 internal amino
acids was used. Given the biologic evidence supporting phos-
phorylation as an activating step, it is possible that the phosphor-
ylation seen in the crystal structure may not represent the true
inactive form of NLRC4.
NLRP1 (DEFCAP, NAC, or NALP1) is the NLR that defined the
inflammasome (Martinon et al., 2002; Moayeri et al., 2012).
Human NLRP1 is genetically linked to a group of autoimmune
and autoinflammatory diseases including vitiligo, autoimmune
thyroid diseases, and type I diabetes (Jin et al., 2007; MagittaImmunity 39, Seet al., 2009). Human NLRP1 contains a
N-terminal pyrin domain, a nucleotide-
binding domain (NBD), a function-to-find
domain (FIIND), LRR, and a C-terminal
CARD domain. The NLRP1 CARD is
comprised of six antiparallel alpha heli-
ces, is similar to other death domain
fold-containing prominent charged
patches (Jin et al., 2013), and is thought
to be the key component that interacts
with the CARD from procaspase-1. How-
ever, human and murine NLRP1 have
very distinct structural components. Mu-
rine NLRP1 proteins do not have the pyrindomain and are encoded by three highly polymorphic paralogs:
Nlrp1a, Nlrp1b, and Nlrp1c. Furthermore, mouse Nlrp1b medi-
ates response to the lethal toxin (LT) of Bacillus anthracis
(Boyden and Dietrich, 2006), whereas human NLRP1 does not.
LT causes cell death due to toxin-induced lysosomal membrane
permeability, cathepsin B release (Ali et al., 2011; Averette et al.,
2009), and ATP leakage (Ali et al., 2011). The activator of human
NLRP1 is less clear although several studies have shown that
muramyl-dipeptide (MDP) can activate overexpressed NLRP1
(Faustin et al., 2007; Gregory et al., 2011). Likewise, overexpres-
sion or RNA interference shows that mouse Nlrp1, when coupled
with NOD2, canmediate inflammasome activation in response to
MDP and titanium oxide (TiO2) (Hsu et al., 2008). However,
recently Nlrp1b/ mice have been generated, which identifies
LT, but not MDP or TiO2, as the activator for murine NLRP1 in-
flammasome (Kovarova et al., 2012). Moreover, Nlrp1b defi-
ciency results in an enhanced in vitro and in vivo pyroptosis,
which occurs independently of IL-1b but is dependent on
caspase-1, and this pyrotopsis profoundly affects pathogenesis.
A separate study used N-ethyl-N-nitrosourea mutagenesis and
found a single residue mutation in the FIIND domain of Nlrp1a
that results in a gain-of-function phenotype (Masters et al.,
2012). This strain produces more caspase-1 and IL-1b but yet
exhibits IL-1 receptor-independent hematopoietic cell death in
response to chemotherapy or viral infection. Thus both reports
underscore a strong pathologic role for Nlrp1 that is related to
cell death but independent of IL-1b and IL-1R, although the
targeted cell death pathway remains to be elucidated.ptember 19, 2013 ª2013 Elsevier Inc. 435
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evasion strategies. DNA viruses contain large genomes that
encode immune evasion proteins and two viral-encoded inflam-
masome evasion proteins have been described. Orf63 of
Kaposi’s sarcoma-associated herpesvirus (KSHV) was found
to encode a NLRP1-like protein that contains the NBD and
LRR domains but lacks the PYRIN and CARD domains present
in human NLRP1 (Gregory et al., 2011). Overexpression and
RNA interference of Orf63 shows that it blocks NLRP1-depen-
dent inflammasome and pyroptosis by blocking inflammasome
complex assembly. Orf63 reduces not only NLRP1 but also
NLRP3 and NOD2-activated inflammasome, indicating a
broader function in inflammasome inhibition. In a second study,
a B cell CLL/lymphoma 2 (Bcl-2) homolog of Vaccinia virus (F1L)
was found to bind and inhibit NLRP1 through a small hexapep-
tide in F1L (Gerlic et al., 2013). Deletion of F1L in Vaccinia virus
caused improved survival of the infected mice accompanied
by increased caspase-1 activation and IL-1b secretion. These
two studies reveal different ways by which viral-encoded pro-
teins target the inflammasome for immune evasion.
NLRP1 is also the first NLR shown to undergo proteolytic pro-
cessing and two cleavage sites have been characterized. The
first is located in the FIIND domain that resides between the
LRR and CARD domains. FIIND shares similarity with the ZU5-
UPA domain of an autoproteolytic protein, leading the authors
to investigate and confirm that the NLRP1 FIIND domain un-
dergoes autoproteolysis (D’Osualdo et al., 2011). Another group
confirmed this finding and found that auto-cleavage of NLRP1
enhances inflammasome activation, suggesting that FIIND pro-
tein processing is an important activation step (Finger et al.,
2012). Another report showed that this C-terminal cleavage
site in mouse FIIND is important for spontaneous inflammasome
activation in a reconstitution system and introduction of an arti-
ficial protease site into an Nlrp1b protein from a LT resistance
strain (NOD) restores spontaneous inflammasome activation
(Frew et al., 2012). A second cleavage sequence was initially
found in the N terminus of rat Nlrp1a protein. Anthrax LT-resis-
tant versus LT-sensitive rat strains are polymorphic at this
cleavage site, which affects the ability of LT to cleave this site.
Cleavable Nlrp1b is associated with LT sensitivity (Levinsohn
et al., 2012). In contrast to the clear association of LT resistance
or sensitivity to cleavage of rat Nlrp1a, mouseNlrp1b variants are
cleaved by LT regardless of LT sensitivity or resistance. This sug-
gests that LT resistance or sensitivity in mice cannot be solely
explained by polymorphisms at this cleavage site (Hellmich
et al., 2012). However, cleavage of this site in mouse Nlrp1b
does have a functional consequence as reported in a recent
paper (Chavarrı´a-Smith and Vance, 2013). These authors noted
that mouse recombinant Nlrp1b can be cleaved by LT at a site
that shares similarity with the rat Nlrp1b cleavage site. Mutation
of this site results in the loss of cleavage by LT and a correlative
loss of inflammasome activation. Furthermore, replacement of
this cleavage site with an artificial TEV (tobacco etch virus) pro-
tease cleavage site results in inflammasome activation in the
presence of TEV, supporting a functional role for the proteolytic
processing of Nlrp1b at this N-terminal site.
Several NLR family members are found to exhibit inflamma-
some function but interestingly these proteins also exhibit other
functions; prominent among them is the negative regulation of436 Immunity 39, September 19, 2013 ª2013 Elsevier Inc.NF-kB activation. How inflammasome activation and NF-kB
inhibition intersect is unclear, although prior work has shown a
negative relationship between NF-kB and caspase-1 activation
in that IKKb (inhibitor of kB kinase b) deletion causes increased
caspase-1 activation and pro-IL-1b processing (Greten et al.,
2007). Becausemany of these NLRs are studied in gene-deletion
mice, this approach lends credence regarding these functional
studies. The following summarizes the findings of these inflam-
masome NLRs.
NLRP6 (PYPAF5) was originally found to synergize with ASC to
cause NF-kB and caspase-1 activation in overexpressed sys-
tems (Grenier et al., 2002). Analysis of Nlrp6/ mice shows
that they are uniformly more susceptible to chemical-induced
colitis and colitis-associated tumorigenesis (Chen et al., 2011;
Elinav et al., 2011; Normand et al., 2011). Meanwhile, one group
has shown thatNlrp6/mice have reduced IL-18 and expanded
pathobiont bacteria, Bacteroidetes (Prevotellaceae) and TM7
microbiota, accompanied by spontaneous and induced colitis
(Elinav et al., 2011). Because Asc–/– and Casp1–/–, caspase-11-
deficient mice show strikingly similar phenotypes, these authors
conclude that NLRP6 is an inflammasome NLR (Elinav et al.,
2011). These studies have been extended to a model for nonal-
coholic fatty liver disease (NAFLD) and nonalcoholic steatohepa-
titis (NASH) and found that NLRP6, NLRP3, and IL-18 negatively
regulate NAFLD and NASH progression (Henao-Mejia et al.,
2012). Two other reports have also studied Nlrp6/ mice in
DSS-induced colitis and colitis-associated tumorigenesis. One
report has shown that Nlrp6 deletion results in enhanced inflam-
mation and inflammatory cytokines including IL-1b mRNA and
epithelial cell proliferation that probably contributes to tumori-
genesis (Chen et al., 2011). This report also showed that
Nlrp6/mice have reduced IL-18 protein without an associated
decrease in pro-IL-18 transcript. Another report found that Nlrp6
is expressed primarily by colonic myofibroblasts, and its deletion
similarly exacerbated chemically induced colitis and tumorigen-
esis. The investigators found a role for NLRP6 in promoting tis-
sue repair, and its absence caused colonic proliferation and
increased chemokines; IL-1b was not significantly altered, and
treatment with an IL-1R antagonist did not affect the disease
but the disease is similar to that exhibited by Asc–/– and
Casp1–/– mice (Normand et al., 2011). In addition to a role in
assembling the inflammasome, another report has shown that
the deletion of Nlrp6 results in resistance to bacterial infections,
accompanied by enhanced NF-kB and mitogen activated
protein kinase (MAPK)-dependent cytokines and chemokine
secretion (Anand et al., 2012). The parallel findings in Asc–/–,
Casp1–/–, and Nlrp6/ mice with reduced IL-18 in these mice
suggest that NLRP6 is most likely an inflammasome, but key
features that define the inflammasome such as NLRP6-depen-
dent pro-caspase-1, IL-1b, and IL-18 processing remain to be
demonstrated. Additionally, the results also show that NLRP6
can attenuate inflammatory mediators.
NLRP7 (PYPAF3) is found in humans and not mice. It was
initially shown to be a negative feedback regulator of IL-1b
secretion in reconstituted inflammasome (Kinoshita et al.,
2005). A genetic study of two families with familial recurrent hy-
datidiform moles (HM), a rare abnormal pregnancy comprised of
hyperproliferating trophoblasts, identified NLRP7 as a candidate
gene (Murdoch et al., 2006), which was confirmed in multiple
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Reviewfamilies and ethnic groups (Kou et al., 2008;Wang et al., 2009). In
a follow-up study, peripheral blood mononuclear cells (PBMCs)
were isolated from six HM patients with different NLRP7 muta-
tions, and all but one secreted reduced IL-1b and TNF-a upon
LPS treatment compared to healthy controls (Messaed et al.,
2011). The report implicates a secretory function for NLRP7
rather than pro-IL-1b processing. The same study showed that
WT NLRP7 inhibits IL-1b maturation whereas a nonsense muta-
tion does not exhibit this function. In contrast, a recent report has
applied RNAi screening and shows that NLRP7mediates inflam-
masome activation by mycoplasma acylated lipopeptide (acLP)
and other acLPs in a human macrophage cell line (Khare et al.,
2012). Inflammasome reconstitution assays reveal that NLRP7
but not NLRP3 or NOD1 causes lipopeptide-induced inflamma-
some, and HM-linked mutations are more potent activators of
the inflammasome. It is possible that the use of different cell
sources, test systems, and activators resulted in these opposing
findings.
NLRP12 (Monarch-1 or PYPAF7) exhibits at least two func-
tions in human macrophage cell lines: as an inhibitor of the
noncanonical and the canonical NF-kB pathway (Lich et al.,
2007; Williams et al., 2005) and as an inducer of ASC speck
formation, a surrogate marker for inflammasome activation
(Wang et al., 2002). Gene-deficient mice have revealed similar
outcomes. Two reports have shown that Nlrp12/ mice
exhibited increased noncanonical and canonical NF-kB activa-
tion as well as strong extracellular regulated kinase (ERK)
induction in chemical-induced colitis and colitis-associated
tumorigenesis models (Allen et al., 2012; Zaki et al., 2011).
Both studies found that the Nlrp12 deficiency results in
prolonged and/or increased cytokine secretion including IL-1b
in the affected tissues. However, a different group has found
that a recombinant Yersinia strain but not several other bacteria
can cause Nlrp12-dependent inflammasome activation (Vla-
dimer et al., 2012). Again, divergent models differentially
affecting cell- or tissue-specific Nlrp12 might explain these
different functions.
NLRC5 is now widely accepted as a inducer of class I major
histocompatibility complex (MHC) glycoprotein expression
(reviewed in Kobayashi and van den Elsen, 2012). NLRC5 also
exhibits diverse effects on innate responses in vitro, but this
review will focus only on its potential role in inflammasome
activation. Three groups have used overexpression and siRNA
targeting of Nlrc5 in a human macrophage cell line, primary
PBMCs, or bronchial cells to link it to inflammasome and cas-
pase-1 activation (Davis et al., 2011; Kumar et al., 2011; Trianta-
filou et al., 2013b). One showed the interaction of NLRC5 with
NLRP3 and their shared function in response to NLRP3-inflam-
masome activators in human macrophage cell lines and primary
cells (Davis et al., 2011). A recent report corroborated the func-
tional and physical interaction of NLRC5 and NLRP3 in bronchial
cells infected with Rhinovirus during inflammasome activation
(Triantafilou et al., 2013b). Finally, a study of Nlrc5/ mouse
cells reveals deficiencies in response to NLRP3 activators
such as monosodium urate (MSU), alum, and ATP (Yao et al.,
2012). However, other Nlrc5/ strains have not exhibited
defects in inflammasome activation, an issue that could arise
as a result of different gene targeting strategies used by these
different studies. In addition, human and mouse NLRC5 mayplay different roles in inflammasome activation, thus resulting
in different findings in these two species.
Noncanonical-Inflammasome-Pathway-Activating
Caspase-11
Caspase-1-deficient mice have long been known to be resistant
to LPS-induced septic shock (Li et al., 1995). However, all exist-
ing Casp1–/– mice were recently shown to also lack caspase-11
as a result of backcrossing a passenger mutation from the
caspase-11-deficient 129 mouse strain into C57BL/6 mice
(Kayagaki et al., 2011). Caspase-1 promotes both pyroptosis
and processing and secretion of IL-1b and IL-18. In contrast,
caspase-11 primarily triggers pyroptosis, although it can induce
IL-1b secretion by a pathway in collaboration with NLRP3, ASC,
and caspase-1 (Figure 2; Kayagaki et al., 2011). To differentiate
these two inflammasome pathways, the caspase-1-activating
platforms are now referred to as the ‘‘canonical inflamma-
somes,’’ and the hypothetical platform(s) that activates
caspase-11 is the ‘‘noncanonical inflammasome.’’ Examination
of caspase-11-deficient mice on the C57BL/6 background re-
veals that most of the known inflammasome agonists activate
the canonical inflammasome pathways independently of
caspase-11. Thus, ATP, cytosolic flagellin, and cytosolic DNA
activate caspase-1 via the NLRP3, NLRC4, and AIM2 canonical
inflammasomes, respectively, in agreement with prior thinking
(Kayagaki et al., 2011). In contrast, caspase-11, and not cas-
pase-1, is detrimental during endotoxic shock (Kayagaki et al.,
2011; Wang et al., 1998). It has been found that caspase-11 spe-
cifically differentiates Gram-negative bacteria that invade the
cytosol from those that remain extracellular or confined to the
vacuole, thus protectingmice against lethal infection byBurkhol-
deria thailandensis and B. pseudomallei. In contrast, vacuolar
bacteria such as S. typhimurium are poorly detected by cas-
pase-11, whereas a DsifA mutant that destabilize the vacuole
and enters the cytosol is detected (Aachoui et al., 2013).
In addition to cytosolic bacteria, caspase-11 will respond to
vacuolar bacteria, but under delayed kinetics (Broz et al., 2012;
Gurung et al., 2012; Kayagaki et al., 2011; Rathinam et al.,
2012). It is hypothesized that this results from aberrant translo-
cation of the caspase-11 agonist from the vacuole into the
cytosol. The notable exception is L. pneumophila where the
DsdhA mutant of L. pneumophila, which aberrantly ruptures
the vacuole, is detected by caspase-11 although vacuolar
L. pneumophila are not (Aachoui et al., 2013). Conversely, similar
infections in LPS-primed macrophages at higher multiplicities of
infection (MOI) results in rapid activation of caspase-11 by wild-
type bacteria but not by T4SSmutants (Case et al., 2013; Casson
et al., 2013). The explanation for these divergent results un-
doubtedly lies in the different priming stimuli and MOIs used.
We hypothesize that at higher MOI in primed macrophages, a
T4SS effector imbalance occurs, resulting in vacuolar leakage
or destabilization.
Several groups have examined the priming requirements of
the caspase-11 pathway (Figure 2). Caspase-11 is normally
nonresponsive, unless macrophages are primed with a signal
that activates the transcription factor STAT1. This can be
achieved by any stimuli that induce IFN-b secretion in an auto-
crine or paracrine manner, such as LPS or poly(I:C), or by direct
application of IFN-b or IFN-g, which both signal through STAT1Immunity 39, September 19, 2013 ª2013 Elsevier Inc. 437
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Review(Aachoui et al., 2013; Broz et al., 2012; Case et al., 2013; Gurung
et al., 2012; Rathinam et al., 2012). The molecular mechanisms
underlying this priming effect are not yet clear.
Cytosolic LPS Activates Caspase-11, Triggering Shock
Independently of TLR4
We (Hagar et al., 2013) and others (Kayagaki et al., 2013) have
identified LPS as the cytosolic agonist detected through
caspase-11 (Figure 2). Caspase-11 responds to cytosolic lipid
A species with five or six acyl groups, but not to species with
four acyl groups, indicating structural specificity. This expands
the role of LPS as a key microbial pattern detected by the innate
immune system: extracellular and vacuolar LPS is detected
through TLR4, whereas cytosolic LPS is detected through cas-
pase-11. Interestingly, both Tlr4–/– and caspase-11-deficient
mice are resistant to classical LPS challenge (Kayagaki et al.,
2011; Takeuchi et al., 1999; Wang et al., 1998). We hypothesize
that endotoxic shock involves a two-step process: (1) TLR4
detects extracellular LPS and primes the caspase-11 pathway;
(2) LPS aberrantly enters the cytosol and activates caspase-
11, whose downstream mediators cause shock. Indeed, mice
primed with sublethal LPS become hypersusceptible to subse-
quent low-dose LPS challenge (LPS / LPS). Priming could
also be accomplished by poly(I:C), as indicated by the fact that
poly(I:C)/ LPS mice also succumb. Although Tlr4–/– mice are
resistant to LPS / LPS challenge, they still succumbed to
poly(I:C) / LPS challenge. Therefore, during endotoxic shock
TLR4 primes the caspase-11 pathway, but can be replaced by
alternate priming stimuli including via TLR3. Indeed, caspase-
11-deficient mice are more resistant to this challenge, although
some mice still succumb. These results corroborate the in vitro
data showing that caspase-11 responds to LPS independently
of TLR4 (Kayagaki et al., 2013; Hagar et al., 2013). These studies
demonstrate that TLR4 is dispensable during experimental
endotoxic shock and proves that a second LPS detection
pathway causes mortality.
Eicosanoid Mediators Triggered by Inflammasome
Activation In Vivo
Poly(I:C)/ LPS challenge results in mortality within 2 hr, which
is kinetically similar to shock triggered after rapid activation of
the canonical NLRC4 inflammasome activation in vivo. To acti-
vate the NLRC4 inflammasome in vivo, the anthrax lethal toxin
was modified to remove the enzymatic subunit and replaced
with flagellin (vonMoltke et al., 2012). This FlaTox injects flagellin
into the cytosol of host cells, where it is detected by the canon-
ical NLRC4 inflammasome. Mice injected with FlaTox die within
30min in the absence of priming, because the NLRC4 pathway is
largely priming independent. This mortality was found to be
independent of IL-1b and IL-18, but rather was due to massive
eicosanoid production, resulting in fluid extravasation, hemo-
concentration, and resulting shock from loss of blood volume.
Mice can be rescued by cyclooxygenase-1 (COX-1) deficiency,
which prevents eicosanoid production (von Moltke et al.,
2012). Similarly, during poly(I:C)/ LPS challenge, COX-1 inhib-
itors rescue themice. Thus, two in vivo models indicate that both
canonical inflammasome pathways activating caspase-1 and
noncanonical inflammasome pathways activating caspase-11
can cause shock via eicosanoid production. The mechanism438 Immunity 39, September 19, 2013 ª2013 Elsevier Inc.by which caspase-1 or caspase-11 trigger eicosanoid produc-
tion remains to be determined but appears to involve calcium
influx activating cyclic phospholipase A2 (cPLA2) and also is
enhanced byMYD88 and TRIF signaling (vonMoltke et al., 2012).
Conclusion
This review provides an updated synopsis of the rapidly evolving
field of the biology of the inflammasome with a focus on the NLR
proteins. Pathways and molecules including mitochondrial
changes, calcium regulators, and ER stress inducers are found
to lie upstream of the NLRP3 inflammasome, and the NLRC4-
NAIP inflammasome is found to interact with its ligand through
NAIP with NLRC4 undergoing posttranslational modification
and activation. Key advances have also been made in NLRP1,
which is found to cause profound changes in pyroptosis and
undergoes posttranslational proteolysis that are necessary for
its activation. In addition, several NLRs are found to exhibit in-
flammasome function. In addition to the canonical caspase-1
activating inflammasome, the noncanonical caspase-11 inflam-
masome is found to be differentially triggered by cytosolic and
vacuolar bacteria and most importantly by cytosolic LPS. It is
apparent that recent progress has generated an arsenal of infor-
mation regarding inflammasomes. Challenges are to understand
how the different activation pathways of inflammasome
converge or diverge and how the different NLR inflammasomes
are activated in molecular terms.
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